Showing 8921-8930 of 18111 results for "".
- Interim Phase 2 Data Reveal Efficacy and Strategic Potential of KYV-101 in Generalized Myasthenia Gravishttps://reachmd.com/news/interim-phase-2-data-reveal-efficacy-and-strategic-potential-of-kyv-101-in-generalized-myasthenia-gravis/2484058/Interim Phase 2 data from Kyverna Therapeutics’ KYSA‑6 study indicate KYV‑101 produced early efficacy signals and an acceptable safety profile in generalized myasthenia gravis (gMG). KYV‑101 is a fully human, autologous CD19 CAR T‑cell therapy intended to induce deep
- Fancy Dress Contact Lenses: Clinical Insights for Safe Halloween Wearhttps://reachmd.com/news/fancy-dress-contact-lenses-clinical-insights-for-safe-halloween-wear/2484063/Decorative contact lenses surge before Halloween and are linked to a seasonal rise in ocular infections, corneal ulcers, and other vision‑threatening complications. According to a
- Discrepancies in Polio Vaccination Reporting: Implications for Surveillance and Laboratory Practiceshttps://reachmd.com/news/discrepancies-in-polio-vaccination-reporting-implications-for-surveillance-and-laboratory-practices/2484070/A recent report found a roughly 20% gap between self-reported and documented polio vaccination among survey participants—an inconsis
- How Global Trade and Travel Influence Mosquito-Borne Disease Spreadhttps://reachmd.com/news/how-global-trade-and-travel-influence-mosquito-borne-disease-spread/2484076/According to a recent report, a global analysis maps how trade and travel have driven introductions of non-native mosquitoes since 1950 and id
- Innovative Management of Larotrectinib Withdrawal Symptoms Using GLP-1 Receptor Agonistshttps://reachmd.com/news/innovative-management-of-larotrectinib-withdrawal-symptoms-using-glp-1-receptor-agonists/2484079/A recent case report describes resolution of larotrectinib withdrawal symptoms after starting semaglutide, a GLP‑1 receptor agonist — an observation with immediate relevance for supportive care teams. The patient developed diffuse, withdrawal‑like myalgias and arthralgias in the set
- Inflammation and Pain in Neurocritical Care: New Insights from Recent Researchhttps://reachmd.com/news/inflammation-and-pain-in-neurocritical-care-new-insights-from-recent-research/2484056/A recent study found that early systemic inflammatory markers did not predict ICU pain burden after aneurysmal subarachnoid hemorrhage (SAH); instead
- Early Peanut Introduction: Real-World Evidence of Allergy Prevention Benefitshttps://reachmd.com/news/early-peanut-introduction-real-world-evidence-of-allergy-prevention-benefits/2484059/Primary-care EHR data show a substantial drop in clinician-diagnosed peanut and overall IgE-mediated food allergies after the 2015 early-introduction guideline and its 2017 addendum. According to the recent
- Advancements in Minimally Invasive and Robotic Surgery for Hepatobiliary and Pancreatic Procedureshttps://reachmd.com/news/advancements-in-minimally-invasive-and-robotic-surgery-for-hepatobiliary-and-pancreatic-procedures/2484067/A large single‑center series (n>200) reports oncologic efficacy and low morbidity after minimally invasive radical cholecystectomy for gallbladder
- Advancements in ctDNA-Guided Therapy for Bladder Cancer: Implications for Clinical Practicehttps://reachmd.com/news/advancements-in-ctdna-guided-therapy-for-bladder-cancer-implications-for-clinical-practice/2484075/A new phase 3 trial offers compelling evidence that circulating tumor DNA (ctDNA) can guide adjuvant treatment decisions in muscle-invasive bladder cancer (MIBC), ushering in a precision medicine strategy that tailors immunotherapy to those most at risk of recurrence. The findings, p
- Systemic Inflammation Markers: No Predictor for Pain in SAHhttps://reachmd.com/news/systemic-inflammation-markers-no-predictor-for-pain-in-sah/2484052/A recent multicenter study found that early systemic inflammatory markers did not predict subsequent ICU pain burden after aneurysmal subarachnoid hemorrhage (SAH), a finding